Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257016 | 0.87 | GAA (0.47) | KMT2AMEN1GAATGM2 | |
| SCHEMBL422363 | 0.82 | EPHX2 (0.52) | LIPEKMT2AMEN1EPHX2EPHX1 | |
| SCHEMBL423894 | 0.79 | LIPE (0.60) | LIPEKMT2AMEN1EPHX2TGM2 | |
| SCHEMBL2292696 | 0.79 | KMT2A (0.54) | LIPEKMT2AMEN1GAAEPHX2 | |
| SCHEMBL420867 | 0.79 | SCN9A (0.43) | LIPEKMT2AMEN1GAAEPHX2 | |
| SCHEMBL421808 | 0.78 | LIPE (0.52) | LIPEKMT2AMEN1EPHX2EPHX1 | |
| SCHEMBL422005 | 0.78 | EPHX2 (0.47) | LIPEKMT2AMEN1EPHX2TGM2 | |
| SCHEMBL421892 | 0.77 | PKM (0.52) | LIPEKMT2AMEN1EPHX2 | |
| SCHEMBL10157300 | 0.76 | EPHX2 (0.48) | LIPEKMT2AMEN1EPHX2EPHX1 | |
| SCHEMBL425024 | 0.75 | EGLN1 (0.53) | LIPEKMT2AMEN1EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| EP-2414332-B1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2414332-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | Shionogi & Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| WO-2010114181-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | LIPE 4481/4885KMT2A 4025/4885MEN1 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.